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SUMMARY
Epigenome-wide association studies (EWAS) pro-
vide an alternative approach for studying human
disease through consideration of non-genetic vari-
ants such as altered DNA methylation. To advance
the complex interpretation of EWAS, we developed
eFORGE (http://eforge.cs.ucl.ac.uk/), a new stand-
alone and web-based tool for the analysis and inter-
pretation of EWAS data. eFORGE determines the
cell type-specific regulatory component of a set
of EWAS-identified differentially methylated posi-
tions. This is achieved by detecting enrichment of
overlap with DNase I hypersensitive sites across
454 samples (tissues, primary cell types, and cell
lines) from the ENCODE, Roadmap Epigenomics,
and BLUEPRINT projects. Application of eFORGE
to 20 publicly available EWAS datasets identified
disease-relevant cell types for several common
diseases, a stem cell-like signature in cancer, and
demonstrated the ability to detect cell-composition
effects for EWAS performed on heterogeneous tis-
sues. Our approach bridges the gap between large-
scale epigenomics data and EWAS-derived target
selection to yield insight into disease etiology.
INTRODUCTION
Common complex diseases, such as autoimmune, metabolic,
and neurodegenerative diseases as well as cancer, typically
involve multiple genetic and non-genetic factors. The search
for genetic factors through genome-wide association studies
(GWAS) has identified thousands of replicated SNPs associated
with many diseases and other complex phenotypes (Welter
et al., 2014). Notably, most of the identified variants were found
to map at non-protein coding regions where their molecular con-
sequences are difficult to evaluate (Paul et al., 2014). The search
for non-genetic factors is more complicated due to the many
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confounding factors, in particular, genetic heterogeneity be-
tween individuals and cell-type heterogeneity in accessible sam-
ple material (e.g., whole blood). Nonetheless, significant prog-
ress has been made following the introduction of systematic
epigenome-wide association studies (EWAS) in 2011 (Rakyan
et al., 2011), including correction of cell-composition effects
(Houseman et al., 2012; Zou et al., 2014; McGregor et al.,
2016; Houseman et al., 2016). Since then, over 250 EWAS
have been conducted (Michels et al., 2013). A large proportion
of these EWAS have correlated DNA methylation (DNAm)
profiles with disease status and environmental exposure in
cross-sectional case-control cohorts. A subset of these studies
reported differentially methylated positions (DMPs) that repli-
cated in independent sample cohorts, e.g., for smoking behavior
(Philibert et al., 2015). Fine mapping of the disease-associated
genetic variants and integrative analysis with cell type-specific
epigenomic datasets suggest a possible causal involvement
of affected regulatory sequences, especially enhancers (Farh
et al., 2015; Kundaje et al., 2015).
Several large-scale initiatives such as the ENCODE (ENCODE
Project Consortium, 2012), Epigenomics Roadmap (Kundaje
et al., 2015), and BLUEPRINT (Adams et al., 2012) projects
have mapped gene regulatory elements across a wide range of
tissues and cell types using a variety of assays. Active regulatory
elements have been shown to concentrate at DNase I hypersen-
sitive sites (DHSs) (Dorschner et al., 2004). The intersection of
these DHSs with common disease-associated variants has
proved to be a powerful approach to identify potential regulatory
variants implicated in the disease (Maurano et al., 2012). This
approach has been implemented as a publicly available web
tool, termed FORGE, and systematically applied to analyze SNP
sets for 260 phenotypes from the GWAS catalog (Dunham
et al., 2015). The functional interpretation of the resulting SNP-
DHS overlaps is that highly associated GWAS SNPs are enriched
for DHSs of specific cell types that are relevant to the etiology of
the disease under investigation. This is because such SNPs are
thought to exert functional changes in affected regulatory ele-
ments (marked by DHSs), which, in turn, can then affect gene
expression and may ultimately result in phenotypic changes.
While genotypes are generally invariable, epigenotypes are
ontogenetically, spatially, and temporally variable. This can
impede the meaningful interpretation of DMPs identified through
EWAS (Michels et al., 2013; Birney et al., 2016; Paul and Beck,
2014). For example, EWAS are often performed on heteroge-
neous tissues (e.g., whole blood) where cell-composition effects,
or only a specific cell type within that tissue, may be driving the
observed epigenetic signal. While significant progress has been
made to reducemajor sources of confounding (reviewed in Liang
and Cookson, 2014; Wilhelm-Benartzi et al., 2013; Rakyan et al.,
2011; Michels et al., 2013; Birney et al., 2016), additional tools
are required to improve EWAS analysis and elucidate disease
mechanisms. To this end, we have developed eFORGE (ex-
perimentally derived Functional element Overlap analysis of
ReGions from EWAS), a bioinformatics tool that informs which
EWAS DMPs are likely to be functional and in which tissue or
cell type. This is achieved by overlap analysis between a DMP
set of choice and reference DHS maps, improving on previous
overlap analyses (Stadler et al., 2011; Slieker et al., 2013).
eFORGE has been implemented both as standalone software
and an interactive web tool, and rigorously tested for per-
formance criteria, including reproducibility, false-positive rates,
and code execution speed. To demonstrate its utility, we
systematically analyzed publicly available EWAS datasets to
explore the suitability of eFORGE for analyzing surrogate tissues
and detecting cell-composition effects, with the ultimate aim of
providing insights into disease mechanisms.
RESULTS
eFORGE Method and Workflow
The main objective of eFORGE is the prediction of disease-rele-
vant cell type(s) from EWAS data generated in heterogeneous
tissues, as illustrated in Figure 1A. eFORGE analyses such
EWAS data generated using Illumina Infinium BeadChips (i.e.,
27k, 450k, and EPIC arrays). For a given set of high-scoring
probes on the array platform (indicated by large black dots in up-
per left panel), eFORGE generates a background of 1,000
random probe sets with matching properties regarding their
location within genes and CpG islands (Tables S1 and S2). It
then overlaps these sets with DHSs for up to 454 selectable
reference samples (tissues, primary cell types, and cell lines)
from the ENCODE, Epigenomics Roadmap, and BLUEPRINT
projects (Data S1). Finally, eFORGE compares the number of
DMPs overlapping DHSs with those obtained by random probes
to calculate enrichment scores for each of the selected cell
types. For a given eFORGE plot, as illustrated in the bottom right
panel of Figure 1A, cell types are shown on the horizontal axis
and the significance (e.g., –log10 binomial p value) is shown on
the vertical axis. Each dot represents an enrichment p value for
a given cell type. Enrichments with multiple testing-corrected q
values <0.05 and <0.01 are shown as pink and red dots, res-
pectively. Samples that do not reach statistical significance (q
value >0.05) are shown in blue.
Assessment of eFORGE Performance
First, we assessed the reproducibility of eFORGE. Each time
eFORGE is run on a dataset, it selects matched background
probes at random. Because of this, the background is different
for each eFORGE analysis. To assess the level of reproducibility
between individual analyses, we compared 1,000 independent
eFORGE runs using the same dataset, which also represents
the default test set made available as part of the stand-alone
andweb-based versions of eFORGE (see also Experimental Pro-
cedures). Using this test set, we obtained a highly consistent
pattern of enrichment for the same target cell types between in-
dividual runs (Figure 1B), demonstrating that eFORGE results are
highly reproducible.
Second, we assessed two methods for the correction of mul-
tiple testing: Benjamini-Hochberg (BH), a false discovery rate
(FDR)-based correction method for independent tests (Benja-
mini and Hochberg, 1995), and Benjamini-Yekutieli (BY), an
FDR-based correction for multiple tests that are not independent
(Benjamini and Yekutieli, 2001). We reasoned that the latter
would be more appropriate in our case as DHSs across different
cell types have been found to be cell lineage dependent (Sterga-
chis et al., 2013). Benjamini-Hochberg correction resulted in one
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false-positive (q value <0.01), after running >2.3 million tests
(8,000 runs of 299 samples each), compared to no false-posi-
tives with BY correction (q value <0.01). Based on this result,
we implemented BY correction for eFORGE analyses (see also
Tables S3 and S4).
Third, we assessed eFORGE computational speed using
different approaches to manage the large decimal p value
numbers resulting from the many statistical tests performed.
The Perl BigFloat and BigInt functions used by FORGE (Dunham
et al., 2015) were slow and, in some cases, even impeded
eFORGE code execution. Switching to using the logarithms of
the values for the binomial test not only reduced the amount of
digits needed in calculation, but also dramatically increased
code execution speed as shown in Figure 1C. We anticipate
that this advancewill become particularly noticeable in the online
version of eFORGE when encountering high user demand.
Inter-consortium Correlation Analysis
One possible caveat when interpreting eFORGE results
could be consortium-specific differences in the generation of
reference datasets used by eFORGE. These include data-
analysis pipelines, experimental protocols (including read
depth specifications), and materials used (i.e., ENCODE pre-
dominantly analyzed transformed cell lines, whereas Roadmap
and BLUEPRINT used primary tissue samples). In order to
quantify any consortium bias on data generation, we applied
the Genomic Efficient Correlator (GeEC) tool (see Experimental
Procedures). This tool can measure the correlation of data
from different consortia and identify drivers of clustering for
Figure 1. eFORGE Overview and Performance
(A) Concept, components, and flowchart of eFORGE: upper-left panel depicts typical EWAS results with top hitsmarked as large black dots that serve as input for
eFORGE. Themain components of eFORGE are controlled by Perl software that uses data from the Roadmap Epigenomics, ENCODE, and BLUEPRINT projects
to compute enrichment and significance profiles (illustrated by middle and bottom left panels). R code is used to generate output graphs (illustrated by bottom
right panel) with predicted target cell types marked in red.
(B) Reproducibility: using the CD14+ tDMP dataset (Jaffe and Irizarry, 2014), 1,000 different runs were performed showing that the variability due to random
background sampling is well below the two eFORGE thresholds (green and red lines) that affect target prediction (shown in log scale). These data indicate high
reproducibility between eFORGE runs.
(C) Runtime: comparison of Perl BigFloat and BigInt (original code, in black) versus logarithm-based code (in blue) for the management of decimal p value
numbers shows up to a 15-fold increase in speed for logarithm-based code. Original code was unable to process 1,000 probes, so data are only shown for probe
sets under 1,000 probes.
(D) GeEC correlation data matrix for DHS/Histone mark data from the Roadmap, ENCODE, and BLUEPRINT projects. Red regions show high positive correlation
(as measured by Pearson correlation coefficient), white regions show no correlation and blue regions show high negative correlation. Grouping of data by
hierarchical clustering agrees with original DHS/Histone mark label (y axis), suggesting a similarity in measurements between different consortia. See also Tables
S1–S5, S6 and Data S1.
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these data. This analysis did not detect any consortium bias on
data generation (Figure 1D; Table S5).
Application to tDMPs
As a positive control, we assessed the ability of eFORGE to iden-
tify the correct tissues and cell type(s) when tested with probe
sets of established tissue and cell-type specificity. In this regard,
we analyzed three sets of previously reported tissue-specific
DMPs (tDMPs) (Lowe et al., 2015) and three sets of cell type-spe-
cific DMPs (cDMPs) (Jaffe and Irizarry, 2014) using consolidated
Roadmap DHS data. Figure 2 shows the resulting heatmap,
which demonstrates the ability of eFORGE to unambiguously
identify the relevant tissues and cell types for each tDMP and
cDMP set (i.e., blood, kidney, lung, monocytes, natural killer
cells, and T cells). To quantify the level at which eFORGE can
detect mixed tissue- and cell type-specific enrichment, we
next assessed its performance onmixed tDMP and cDMP probe
lists. Figure S1A shows the result for a mixture of tDMPs from
lung and kidney tissues (Lowe et al., 2015). Although both tissues
were predicted correctly in eFORGE, the tissue-specific signal
was lower, due to a lack of specific enrichment for the mixed
sets in each of the cell types. Figure S1B shows the correspond-
ing results for mixed cDMPs. Here, sets of 148 B cell-specific
and 148 monocyte-specific cDMPs (Jaffe and Irizarry, 2014)
were mixed, and again the corresponding cell types were
Figure 2. eFORGE Analysis of tDMPs and cDMPs
Results show ability to predict target tissues from known tissue-specific differentially methylated positions (tDMPs) and cell type-specific DMPs (cDMPs): the
heatmap is a composite of results for the top 1,000 tDMPs for blood, kidney, and lung (Lowe et al., 2015), and top cDMPs for CD14+, T cells, and NK cells (Jaffe
and Irizarry, 2014). With tDMPs and cDMPs, we have the advantage of a known prior tissue- or cell type-specific association. We can thus test whether the
eFORGE tool identifies the correct tissue. The color-coded enrichment results show that eFORGE identified the correct tissue or cell type each time, with no false-
positives. This confirms the tool can signal when regions are associated by DNAm with a specific cell type. See also Figure S1 and Data S2, S3, S4, and S5.
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correctly predicted. Taken together, we provided evidence that
eFORGE can identify the correct target tissues and cell types
from individual and mixed probe sets.
Application to EWAS Data
Next, we applied eFORGE to analyze published EWAS data.
First, we considered all EWAS compiled in a review article
(Michels et al., 2013) that analyzed at least 100 samples using
Illumina Infinium BeadChips. This qualified 44 datasets for
eFORGE analysis, of which 20 showed eFORGE signal (q value
<0.05). 14 studies showed an enrichment pattern specific to
particular tissues. For instance, we observed blood-specific pat-
terns for six blood-based EWAS, and stem cell-specific patterns
for five cancer and aging EWAS (Figure 3). The genome-wide
distribution of hits from these studies is shown in Figure 4. In
addition, we found a larger average sample size for studies
that present eFORGE signal (average n = 527) compared to
those studies that did not (average n = 191). Taken together,
these results suggest that tissue-specific enrichment patterns
are widespread among EWAS and that eFORGE demonstrates
the capacity to detect these patterns.
Second, to provide specific examples of eFORGE analysis, we
assessed the ability of eFORGE to predict disease-relevant cell
types from EWAS conducted on immune blood cells for three
autoimmune diseases: rheumatoid arthritis (RA) (Liu et al.,
2013), systemic lupus erythematosus (SLE) (Coit et al., 2013),
and Sjo¨gren’s syndrome (Altorok et al., 2014). For these dis-
eases, it is assumed that blood is the main affected tissue. We
performed eFORGE analyses for each of these diseases using
the reported top 100, 86, and 753 probes and consistently found
tissue-specific enrichment for immune effector cells and thymus
(Figure 5). Specifically, eFORGE results for the EWAS on RA
pointed to CD14+ cells as the most highly enriched cell type (q
value = 5.53e-04), indicating a tendency for cell-composition-
corrected RA-associated DNAm changes to co-locate with
CD14+ DHSs. Indeed, the accelerated maturation of CD14+ cells
is a hallmark in RA (Hirohata et al., 1996). For the EWAS on SLE,
we observed confirmatory enrichment in DHSs specific to T cells
(q value = 2.56e-05). T cells, in particular CD4+ T cells, play an
essential role in the development of SLE (Yin et al., 2015) and
have previously been proposed as targets for the treatment of
Sjo¨gren’s syndrome (Singh and Cohen, 2012). Consistent with
these findings, eFORGE also pointed to an independent T cell
signal for DMPs identified in the Sjo¨gren’s syndrome EWAS (q
value = 1.31e-49).
Third, we assessed whether eFORGE can uncover patterns in
published EWAS data that would inform the functional interpre-
tation of the statistical findings. Using the top 1,000 hypomethy-
lated regions for an EWAS on multiple sclerosis (MS) (Huynh
et al., 2014), we generated eFORGE plots for several DHS refer-
ence sets (Figure 6A). We observed a tissue-specific enrichment
in immune cells, which is unexpected for a study performed on
pathology-free brain tissue. To support this observation, we car-
ried out additional eFORGE analysis using histone marks (Kun-
daje et al., 2015) that showed an enhancer-specific signature
(H3K4me1) underlying this DHS enrichment (Figure 6B). We
then intersected the top 1,235 hypomethylated regions from
the study that gave rise to the observed immune signal with
the locations of active enhancers (n = 1,158) previously identified
in microglial cells (Lavin et al., 2014). These immune cells consti-
tute up to 15% of all cells in the mammalian CNS (Xavier et al.,
2014). A Fisher’s exact test confirmed significant co-localization
of the microglial-specific active enhancers (p value: 2.70e-07,
odds ratio [OR]: 5.88, 95% confidence interval [CI]: 3.19–9.96),
suggesting that microglial enhancers may be potential drivers
of the MS EWAS signal. In conclusion, eFORGE analysis of pub-
lished MS EWAS data uncovered tissue-specific patterns, sug-
gesting potential molecular mechanisms relevant to the etiology
of the disease.
Fourth, we examined whether eFORGE can be used for the
interpretation of EWAS that use surrogate tissues. In these
studies, DNAm changes are measured in easily accessible tis-
sues such as whole blood or buccal cells rather than the target
tissue that is most relevant to the disease. It has been sug-
gested that DNAm changes in surrogate tissues reflect epige-
nomic perturbations found in the target tissue (Lowe and
Rakyan, 2014). An alternative possibility is that the observed
epigenetic signature does not mimic methylation changes in
the target tissue but is specific to the surrogate tissue. We
performed eFORGE analysis on the top 110 regions from an
EWAS on ovarian cancer, which was performed on whole blood
using a pre-treatment discovery cohort. We found enrichment
for CD14+ cells (q value = 1.37e-12, Figure 6C), but not for ovary
(q value = 1) or solid cancer tissues (q value = 1). In addition, the
observed myeloid/lymphoid enrichment patterns suggested
cell-composition effects, as only myeloid regions showed
enrichment, raising the possibility that these DNAm differences
were caused by an increase in myeloid cell numbers in one of
the groups. While a similar immune signature had been identi-
fied before, in addition to cell-composition effects (Teschen-
dorff et al., 2009; Houseman et al., 2012; Li et al., 2014), we
used an alternative approach to support this finding. Specif-
ically, we were able to exclude ovarian signal and provide evi-
dence for which myeloid cell types may drive the EWAS signal.
For example, DHS enrichment was not observed for megakar-
yocytes (Figure 6C). In summary, eFORGE analysis of the top
hits from an EWAS on ovarian cancer pointed to cell-composi-
tion effects driven by a myeloid-specific immune response to
this cancer type, rather than an epigenetic change in peripheral
blood that mimics a change in the methylome of the ovarian
cancer tissue.
Finally, we showed that eFORGE detects tissue-specific pat-
terns in cancer EWAS data. We analyzed five cancer EWAS:
breast cancer (Fang et al., 2011), colorectal cancer (Kibriya
et al., 2011), sporadic colorectal cancer (Laczmanska et al.,
2013), clear cell renal cell carcinoma (Arai et al., 2012), and adre-
nocortical carcinoma (Barreau et al., 2013). Using the top 330,
450, 240, 801, and 362 EWAS hits, respectively, we performed
eFORGE analysis for each DMP set, and identified enrichment
in stem cells but not in breast, intestine, or renal tissues across
the five studies (Figure 7). This suggests that many regulatory
elements affected by cancer epigenetic reprogramming may
be stem cell like. This is consistent with previous findings that
DNAm changes in cancer tissue aid the emergence of a possible
stem cell phenotype (Widschwendter et al., 2007). In conclusion,
application of eFORGE to cancer EWAS data provided evidence
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for a stem cell-like enrichment across all five studies, which
warrants further investigation.
DISCUSSION
We have developed eFORGE, a tool that highlights DMPs
identified through EWAS that are likely to be functional in a cell
type- and tissue-specific context. Its development represents
an addition to the currently limited toolbox available for compre-
hensive analysis and interpretation of EWAS data. Both the
standalone and web-based versions of eFORGE have been sub-
jected to rigorous performance assessment with regards to
false-positive rates, reproducibility, and speed to ensure ability
to cope with high user demand.
Figure 3. Aggregated Enrichment Statistics for Studies with eFORGE Signal from a Recent Review
Studies were obtained from the review by Michels et al. (2013). This heatmap shows the enrichment statistics (presented as –log10(binomial p value)) for an
unbiased selection of EWAS (n = 20 studies, eachwith at least 100 samples).Many of these studies show an enrichment pattern specific to particular tissues, such
as blood (blue box, seven studies) and stem cells (red box, five studies). In addition, one ccRCC study shows a kidney specific enrichment and one CLL study
presents a lung-specific enrichment (lung tissue and IMR90). Other patterns are more mixed (yellow box, six studies). Of the seven blood-enriched studies, six
were performed in blood and one was performed in breast cancer tissue, which may contain immune cells. All five studies that show a stem cell-specific
enrichment are exclusively cancer or aging EWAS. Of the six studies that show a mixed enrichment, there is evidence of different components underlying
variation. For example, the EWAS on child maltreatment performed on salivary DNA, despite showing enrichment for many tissues, has blood cell types as the
highest categories. Work remains to be done to refine these mixed signals and define the components that are driving enrichment for several different tissue
types. See also Table S7.
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SNPs identified through GWAS have been systematically
probed for enrichment at regulatory elements marked by DHSs
(Maurano et al., 2012). This analytical approach has recently
been implemented in the FORGE tool, which enables an auto-
mated analysis workflow (Dunham et al., 2015). Complementing
FORGE for epigenetic analysis, we have developed eFORGE to
provide large-scale, tissue-specific DHS enrichment analysis for
DMPs identified through EWAS. While using parts of the FORGE
framework (Dunham et al., 2015), eFORGE uses a different,
EWAS-specific background and contains several features not
included in FORGE, such as a faster scaling of the binomial
test and histone marks as a dataset additional to DHSs.
The main applications of eFORGE are the analysis of EWAS
data to predict disease-relevant cell types and potential cell-
composition effects, as well as quality-control analysis for
studies on tissue-specific DNA methylation. We have provided
evidence that eFORGE analysis of tDMPs correctly predicts
the relevant tissue through tissue-specific DHS enrichment pat-
terns (Figure 2). In this way, sets of tDMPs can be linked to the
corresponding tissue in an independent manner. This link can
also be used in the inverse sense to detect regions with a poten-
tial tissue-specific regulatory function, by using algorithms to
detect probe sets with a high tissue-specific eFORGE score.
eFORGE is also designed to aid downstream functional follow-
up of DMPs by providing tissue-specific DHS overlap results in
the form of tables, with data for specific genomic regions.
DHSs are markers of cis-regulatory elements (Dorschner et al.,
2004), and DNAm changes in these regions may be associated
with functional consequences (Sch€ubeler, 2015). Such func-
tional links could be confirmed through experimental assays,
including chromatin conformation capture techniques and epi-
genome editing using CRISPR/Cas9 (Ko¨eferle et al., 2015).
eFORGE can also be used to assess cell-composition effects
in EWAS, providing a complementary approach to methylation-
based tools. When heterogeneous tissues are analyzed in
EWAS, a proportion of the observed differential DNAm signal
can be due to cell-composition effects (Houseman et al., 2012,
2016; Paul and Beck, 2014). eFORGE can identify these
Figure 4. Karyotype View of EWAS Hits and Bar Chart of EWAS Tissues
(A) This karyotype view was obtained taking top ten study hits from each of the 20 EWAS with eFORGE signal (taken from Michels et al., 2013) and performed
using ensembl KaryoView (http://www.ensembl.org/Homo_sapiens/Location/Genome). Many EWAS exclude probes from sex chromosomes as part of study
analysis, and therefore there is an absence of top hits in these chromosomes on the graph. Apart from this, there seems to be no strong bias in the distribution of
EWAS hits along the genome.
(B) Bar chart indicating analyzed tissue for 20 EWAS with eFORGE signal from Michels et al. (2013). As is to be expected for an easily accessible tissue, blood is
the most analyzed category, with ten studies.
See also Table S7.
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cell-composition effects by detecting tissue-specific DHS en-
richment based on genomic location, not DNAm values. Unlike
alternative methods for detecting cell-composition effects (Zou
et al., 2014; Houseman et al., 2012, 2016), eFORGE provides
the user-friendly option of web-based analysis.
eFORGE analysis is, however, not without limitations. Despite
the fact that eFORGE can detect cell-composition effects, the
user must interpret whether a given enrichment is driven by con-
founding cell-composition effects or by true cell type-specific
effects. Based on the data presented here, strong bias toward
one cell type for an EWAS performed on heterogeneous tissue
is more likely an indication of cell-composition than cell type-
specific effects. The need for a more accurate interpretation re-
quires complementary methods for cell-composition detection
and correction to be used and also highlights the requirement
of experimental validation. In addition, eFORGE can only analyze
cell types for which DHS data are available. Although the current
eFORGE database contains 454 samples, many cell types are
still not represented. To consider these, we have to recur to alter-
native analyses, as shown in our analysis of microglial enhancer
enrichment outside of eFORGE.
In conclusion, we anticipate eFORGE to contribute to the chal-
lenging task ahead of translating the increasing number of DMPs
identified through EWAS into relevant molecular mechanisms.
EXPERIMENTAL PROCEDURES
DNase I Data
DNase I data from the ENCODE, Roadmap Epigenomics, and BLUEPRINT
projects were downloaded and, if necessary, processed using the Hotspot
method (see Supplemental Experimental Procedures). Fastq and BAM files
for BLUEPRINT samples (listed in Table S6) are available at the European
Genome-phenome Archive under accession number EGAD00001002713.
EWAS DMP Data
A list of 44 450k- and 27k-based EWASwas analyzed with eFORGE. The list of
20 studies with eFORGE signal is contained in Table S7. Studies were selected
Figure 5. eFORGE Analysis of Autoimmune EWAS
Top panel shows a blood (predominantly T cell), intestine, and thymus-specific signal for 86 probes from an EWAS on SLE. Middle panel shows a more general
pattern of enrichment, with a strong blood signal, with CD14+ cells as the highest category, for a set of 100 RA EWAS probes. Bottom panel shows a blood
(predominantly T cell) and thymus-specific enrichment for a set of 753 probes for an EWAS on Sjo¨gren’s syndrome. Probe lists were obtained from the
supplementary files of the studies (Coit et al., 2013; Liu et al., 2013; Altorok et al., 2014).
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from Table S1 of a review on EWAS (Michels et al., 2013), taking only studies
with a number of samples equal to or above 100. eFORGE analysis of DMP
sets was performed for DNase I hotspots from ENCODE, BLUEPRINT, and
Roadmap Epigenome projects, with background DMP sets from the Illumina
450k or 27k array where appropriate. For the 27k array background, only
probes shared with the 450k array were used. Notably, 13 of the EWAS
selected from the aforementioned review did not report top probes. This
lack of reporting top probe IDs is an important and not previously reported
finding, constituting a major limitation for EWAS reproducibility, in addition
to hindering eFORGE analysis of published studies. We urge the community
to embrace the open and clear reporting of EWAS results, including top
study hits.
Preparation of eFORGE Overlaps
An SQLite database (http://www.sqlite.org) containing the overlaps for
the Infinium Illumina 450k array (Bibikova et al., 2011) cg probes with the
BLUEPRINT, ENCODE, and Roadmap Epigenome DNase I hotspots was
incorporated into the eFORGE tool. The HumanMethylation450 v.1.2
Manifest File with data from all the cg probes on the 450k array was
used to prepare this database (https://support.illumina.com/array/array_kits/
infinium_humanmethylation450_beadchip_kit/downloads.html).
We compared the 450k array cg probe data to the indexed DNase I hotspots
using the bedtools tool (Quinlan and Hall, 2010). The overlaps for each cg
probe were stored in an SQLite DB, organized by datasets. For each cg probe,
a binary string was generated, representing the presence or absence of an
overlap with a hotspot in each dataset (either Roadmap, BLUEPRINT, or
ENCODE).
Background Probe Parameters
eFORGE evaluated the input DMP set by comparing it to 1,000 background
DMP sets. The probes in the background sets were matched to the probes
in the input set using annotation (i.e., if one probe from the input set was in a
promoter, then its matching probe in each of the 1,000 background sets
was also in a promoter). The annotation categories used for this matching pro-
cess were ‘‘Gene annotation’’ (i.e., 1stExon, 30 UTR, 50 UTR, Body, IGR,
TSS1500, TSS200) and CpG Island annotation (i.e., Island, Shore_Shelf, and
NA or ‘‘open sea’’). All possible combinations of these two levels resulted in
21 different background bin categories. The CpG island annotation categories
‘‘Shelf’’ and ‘‘Shore’’ were merged to produce enough probes in each back-
ground bin category; i.e., more than 1,000. The 450k array Illumina annotation
(Bibikova et al., 2011) was used to create these data categories (Tables S1
and S2).
eFORGE Analysis
Input of DMPs into eFORGE can be in any of two forms: as Illumina 450k/27k
probe IDs or as BED format (BED format should be zero based and the chro-
mosome should be given as chrN, as genomic location on human genome as-
sembly GRCh37). Genome coordinates are sufficient to identify probe IDs if
these are not provided in BED format. We suggest a minimum of 20 and a
maximum of 1,000 probes. If a DMP is not present on the 450k array (or the
27k array probes shared with the 450k array), it is excluded from the analysis.
We added a 1-kb proximity filter in order to avoid the biases of testing groups
of proximal probes in eFORGE: methylation correlation among closely located
CpGs could mean we would be testing the same change more than once.
Probes from input are selected at random by the filter, and any probe within
1 kb of any already selected probe is excluded. The choice of selecting 1 kb
as a limit for filtering was based on previous data showing strong correlation
of DNA methylation levels between CpGs fewer than 1 kb apart (Eckhardt
et al., 2006).
Overlaps are retrieved from the eFORGE database for each analyzable
probe in the input set. The tool records a count of total hotspot overlaps for
each DNase I sample (cell) for the test probe set. eFORGE selects 1,000
matching background probe sets that contain an equal number of probes to
the test probe set, matching for gene annotation and CpG island annotation
as described above. Retrieval of overlaps from the database for each of the
probes in each of the background probe sets then occurs. The tool records
an overlap count for each background set in each DNase I sample. For each
test probe set, eFORGE obtains the binomial p value for the test set overlap
count. This binomial p value is calculated for the test set overlap count relative
to the total number of tested probe sets. The binomial test was chosen over the
hypergeometric test due to the important computational speed advantages it
offers, which are further highlighted considering the high number of tests per-
formed by eFORGE.
eFORGE Outputs
Tabular and graphic descriptions of the enrichment of overlap for the test
DMPs are generated by eFORGE for each DNase I hotspot sample. The tool
outputs a tab-separated values (TSVs) file, which includes columns for Z
score, binomial p value, cell, tissue, datatype, filename of the sample hotspots,
DMPs that contribute to the enrichment, the GEO accession for each sample,
and the BY adjusted q value. An interactive table containing these data is
generated using the Datatables (https://datatables.net/) plug-in for the jQuery
JavaScript library accessed through the rCharts package (http://ramnathv.
github.io/rCharts/).
In terms of graphical visualization of eFORGE output, FORGE scripts (Dun-
ham et al., 2015) were adapted with minor modifications. Briefly, the –log 10
(binomial p value) is presented by cell sample in each of the graphic outputs.
Base R graphics (http://www.r-project.org) are used to generate a pdf graphic.
eFORGE generates the interactive JavaScript graphic using the rCharts
package (http://ramnathv.github.io/rCharts/) to interface with the dimple d3
libraries (http://dimplejs.org). In the pdf and the interactive graphic cells are
grouped alphabetically within each tissue (tissues, in turn, also follow alpha-
betical order). The coloring of results by BY-corrected q value in each of the
graphics is consistent, blue (q value >0.05), pink (q value <0.05), and red (q
value <0.01).
Figure 6. eFORGE Analysis of Surrogate Tissue and Multiple Sclerosis EWAS
(A) DHS analysis of multiple sclerosis EWAS. Upper panel shows eFORGE blood, spleen, and thymus enrichment in Roadmap Epigenomics data for top 1,000
hypomethylated DMPs (ranked in the study by likelihood ratio test and Fisher’s method FDR q value). Lower panel shows enrichment for macrophages and
monocytes in an analysis of the same regions with BLUEPRINT data.
(B) Histone mark analysis of multiple sclerosis EWAS. Panel shows enrichment for top 1,000 study hypomethylated DMRs. Cell type-specific scores are colored
by FDR q value. Cell types with q values below 0.01 for histonemodifications representative of enhancers (H3K4me1) are shown in red, promoters (H3K4me3) are
shown in purple, and polycomb-repressed regions (H3K27me3) are shown in green. Cell types with q values between 0.01 and 0.05 for the histone modification
representative of promoters (H3K4me3) are shown in light purple. Cell types with q values above 0.01 for all other histone modifications are shown in blue.
H3K36me3 (transcribed regions) and H3K9me3 (a marker for heterochromatin) did not present any significant cell type-specific enrichment patterns. Analyzed
regions show enrichment for H3K4me1 (and, at a lower level, H3K4me3) in blood cells.
(C) Analysis of surrogate tissue EWAS: the three panels (ENCODE, BLUEPRINT, and consolidated Roadmap, from top to bottom) show enrichment for monocyte,
macrophage, and AML for an ovarian cancer prediction EWAS measured on whole blood. There is no enrichment for any other tissue (including lymphoid cells,
ovarian tissue, and, interestingly, megakaryocytes). This supports a myeloid-lineage-specific DHS enrichment for top regions from this EWAS. By discarding
enrichment in megakaryocyte regions, and showing enrichment for acute promyelocytic leukemia cell lines (NB4 and HL-60), the lineage-specific component of
this tissue-specific signal points to a divergence that occurs after differentiation from the common myeloid progenitor and is suggestive of an event during
myeloblastic differentiation. This DHS enrichment pattern extends to the myeloblast branch of the myeloid lineage, pointing to these regions being active in the
myeloblast, which would be the cell of origin of this tissue-specific signal. This enrichment pattern shows cell types that drive the proposed myeloid/lymphoid
imbalance causing the methylation signal observed (Teschendorff et al., 2009; Houseman et al., 2012; Li et al., 2014).
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eFORGE Reproducibility
A default probe set of 11 monocyte-specific DMPs was run 1,000 times on
eFORGE, and we plotted a resulting longitudinal set of CD14+ category q
values for these runs (Figure 1B).
False-Positive Testing
We tested eFORGEBY correction with sets of 5, 10, 15, 20, 30, 40, 50, and 100
randomly selected probes, performing 5,000 analyses for both Roadmap Epi-
genomics and ENCODE data. We did not obtain any false-positives (at a q
Figure 7. Analysis of Cancer EWAS
This heatmap shows a stem cell-like signature for regions from five cancer EWAS, through color-coded enrichment –log10(q value). The left column
depicts results for 330 top probes from a breast cancer metastatic behavior EWAS (Fang et al., 2011), the second column from the left shows results for 450
probes from a colorectal carcinoma EWAS (Kibriya et al., 2011), and the central column shows results for 240 probes from a sporadic colorectal cancer EWAS
(Laczmanska et al., 2013). The next column on the right shows results for 801 probes from an adrenocortical carcinoma EWAS (Barreau et al., 2013), and the last
column on the right shows results for 362 probes from a clear cell renal cell carcinoma EWAS (Arai et al., 2012). All five studies showed intermediate enrichment (q
value <0.05) of at least one eFORGE ‘‘ES cell’’ or ‘‘iPSC’’ category. Aside from this stem cell-like signature, no other shared tissue category is enriched across the
five probe lists.
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value <0.01) for any of these analyses. We did, however, obtain false-positives
at a q value <0.05 (0.36%), but this is only indicated to be an intermediate level
of significance in eFORGE. The false-positive rates at a q value <0.05 do not
show a clear tendency with the size of the probe sets (see Tables S3 and
S4). Most of the q values below 0.05 come from a few probe sets, signaling
that most FP come from random sets that are borderline for many tissues/
cell lines. This supports the notion that it is highly improbable to obtain
eFORGE tissue-specific enrichment with random probe lists.
Comparison of BH and BY
8,000 sets ranging between five and 100 DMPs were run on eFORGE using
both BH and BY multiple testing correction methods. As 299 samples were
analyzed for each of the 8,000 DMP sets, there is a total number of
2,392,000 sample tests. Out of these random tests, one false-positive was re-
corded for BH, and zero were recorded for BY, at a significance level of 0.01.
Addition of New Data to eFORGE Database
All the code for generating the eFORGE database from scratch is openly avail-
able on GitHub (see https://github.com/charlesbreeze/eFORGE/blob/master/
database/README.txt and examples in the same directory). Data from a new
project can be added as a table to the modular SQLite database. In addition,
indications are provided for the production of bitstring tables from raw data.
GeEC Analysis
Datasets used for GeEC correlation analysis were taken from the IHEC Data
Portal (http://epigenomesportal.ca/ihec/) as of March 2016. They correspond
to 508 DNase sequencing (DNase-seq) datasets generated by ENCODE,
Roadmap, and BLUEPRINT, as well as 1,277 chromatin immunoprecipitation
sequencing (ChIP-seq) datasets for five core histone marks (H3K4me1,
H3K4me3, H3K36me3, H3K27me3, and H3K9me3) generated by ENCODE
and Roadmap. These 1,785 datasets were processed with the Genomic Effi-
cient Correlator (GeEC) tool to first average the signal of each dataset in
non-overlapping bins of 10 kb (excluding the ENCODE blacklisted regions)
and then to calculate a matrix of the pairwise Pearson product-moment corre-
lation coefficients (r). Hierarchical clustering (using the 1-r distance metric and
the average linkage method) was then conducted, and the principal clusters
were annotated.
Adjusted Rand Index (ARI) results were also used to validate the accuracy of
the clustering by using the IHEC-provided metadata describing every dataset
for three categories of labels (assayType, cellType, consortium). The tree
generated through hierarchical clustering is cut at the appropriate height to
obtain a number of clusters equal to the number of distinct labels in each
category and then used to calculate the ARI scores. ARI values were calcu-
lated using the ‘‘average’’ linkage method.
tDMP Analysis
We extracted normalized samples from Marmal-aid (Lowe and Rakyan, 2013)
for tissues that contained a minimum of 50 samples. We used the dmpFinder
function in minfi (Aryee et al., 2014) to make an initial call of tissue-specific
methylation differences. Two categories were defined to perform this for
each tissue: group 1 contained the tissue of interest, and other tissues were
included in group 2.We used the top two probes for each of the tissue-specific
calls to visually inspect the data. Any samples that were found to be closer to
the mean of group 2 than group 1 were removed. The final calls were then pro-
duced using the remaining samples. We randomly selected 50 samples for
each tissue, and we then followed a similar procedure to the above, calling dif-
ferences using dmpFinder. Data S2 contains the IDs of the samples used in the
analysis. Data S3, S4, and S5 contain the calls for three of the tissues for all
probes.
cDMP Analysis
We obtained data from Table S2 of a cell type-specific methylation paper by
Jaffe and Irizarry (2014). cDMP selection was based on a given probe having
the lowest methylation value for a given cell type when compared to the other
cell types, and this low methylation value being lower than the next closest
methylation value by 0.4.
Source Code
The source code for eFORGE is available on GitHub at https://github.com/
charlesbreeze/eForge. It includes the code for the standalone tool, the web-
server, and the scripts to build or extend the database, although a pre-
compiled eForge.db sqlite database and background selection hash tables
are readily available at http://eforge.cs.ucl.ac.uk/?download. Code variants
(e.g., probe weighting) are discussed in the Supplemental Experimental Pro-
cedures. eFORGE has been successfully installed and run on Red Hat Linux
and OS X 10.9.5.
ACCESSION NUMBERS
The accession number for the BLUEPRINT data reported in this paper is EGA:
EGAD00001002713.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, seven tables, and five data files and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2016.10.059.
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